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Circadian rhythms refer to biologic processes that
oscillate with a period of 24 hr. These rhythms are
sustained by a molecular clock and provide a
temporal matrix that ensures the coordination of
homeostatic processes with the periodicity of envi-
ronmental challenges. We demonstrate the circadian
molecular clock controls the expression and function
of Toll-like receptor 9 (TLR9). In a vaccination model
using TLR9 ligand as adjuvant, mice immunized at
the time of enhanced TLR9 responsiveness pre-
sented weeks later with an improved adaptive
immune response. In a TLR9-dependent mouse
model of sepsis, we found that disease severity
was dependent on the timing of sepsis induction,
coinciding with the daily changes in TLR9 expression
and function. These findings unveil a directmolecular
link between the circadian and innate immune
systems with important implications for immunopro-
phylaxis and immunotherapy.INTRODUCTION
Nearly all organisms have developed mechanisms for antici-
pating environmental changes in order to optimize their survival.
Circadian rhythms are autonomous, self-sustained,24 hr oscil-
lations in biologic processes entrained by environmental cues,
most notably the daily changes in light intensity. Blue light acti-
vates a specific group of photoreceptors in the retina connected
to the suprachiasmatic nuclei in the hypothalamus, which
entrains peripheral circadian clocks via neuroendocrine signals
(Bell-Pedersen et al., 2005). At the molecular level, this 24 hr
rhythmicity is perpetuated by a set of transcription-translation
feedback loops controlling the expression of so-called clock
genes that comprise the molecular circadian clock (Dibner
et al., 2010).
Light and daily rhythms are thought to have a strong influence
on immune function (Roberts, 2000). Several studies have
described circadian variations in different immune parameters
such as lymphocyte proliferation, antigen presentation, and
cytokine gene expression (Arjona and Sarkar, 2005; Esquifino
et al., 1996). Many of these parameters, including circadianoscillations in cytokine levels, are recapitulated in both mice
and humans (Arjona and Sarkar, 2006; Holzheimer et al., 2002;
Petrovsky and Harrison, 1998; Petrovsky et al., 1998). It is
becoming increasingly evident that disruption of daily rhythms
(e.g., sleep deprivation, jet lag) affects the immune response
(Bovbjerg, 2003; Majde and Krueger, 2005; Redwine et al.,
2004). In addition, the fact that both the autonomic nervous
system and the neuroendocrine system (both displaying a strong
daily rhythmicity) have been shown to modulate cytokine
production, leukocyte trafficking, proliferation, and apoptosis
further supports the notion that the light-dark cycle may influ-
ence some immune responses (Petrovsky, 2001). Many compo-
nents of inflammation (such as proinflammatory cytokines)
exhibit circadian patterns in humans, typically peaking during
the night (Scheff et al., 2010), and several inflammatory diseases
such as sepsis (Hrushesky and Wood, 1997) and rheumatoid
arthritis (Kowanko et al., 1982) show diurnal variations in their
severity.
The recognition ofmicrobial infection by innate immune cells is
critical for the overall host immune response (Iwasaki and Medz-
hitov, 2004). The success of the host immune defense against
infections is dependent on the ability of the cells to detect the
presence of the invading pathogen (Medzhitov and Janeway,
2000). One the most important advances in immunology has
been the identification of an evolutionary conserved family of
proteins that recognize conserved pathogen-associated molec-
ular patterns (PAMPs). Microbial molecules can be recognized
by these pattern-recognition receptors (PRRs) that are ex-
pressed in innate immune cells such as macrophages and
dendritic cells (DCs) (Medzhitov, 2001). Upon recognition of
microbial components, PRR signaling results in the upregulation
of costimulatory molecules as well as in the production of type I
interferon and inflammatory cytokines, leading to DCmaturation,
efficient Ag presentation, and establishment of adaptive immu-
nity (Akira et al., 2001). Among all the different PRRs described
so far, Toll-like receptor 9 (TLR9) is unique in the sense that it
recognizes bacterial and viral DNA (Lund et al., 2003) as well
as synthetic oligonucleotides. The CpG-motif dependency of
TLR9 activation is restricted to synthetic ligands on the basis
of phosphorothioate-modified DNA. Natural DNA (phospho-
diester sugar backbone) drives TLR9 activation sequence inde-
pendently, as is the case for RNA recognition mediated by other
PRRs (Haas et al., 2008).
The aim of this study was to determine whether innate immune
pathogen recognition mechanisms are under circadian control
and to assess the tentative consequences in innate and adaptiveImmunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc. 251
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Circadian Control of Toll-like Receptor 9immune responses. Here, we provide evidence showing that
TLR9 expression and function was modulated by core circadian
molecular clock components. The circadian regulation of this
innate immune pathway shaped subsequent long-term adaptive
immune mechanisms. Thus, the magnitude of anamnestic
responses in the context of an immunization adjuvanted with
a TLR9 ligand correlated with daily variations in TLR9 respon-
siveness. In a TLR9-dependent model of sepsis, we found that
disease severity was dependent on the timing of sepsis induc-
tion, which correlated with daily changes in TLR9 expression
and function. These findings unveil a direct molecular link
between the circadian and innate immune systems with impor-
tant implications for immunoprophylaxis and immunotherapy.
RESULTS
Defective TLR9-Dependent Cytokine Response
in Per2Brdm1 Macrophages
We initially hypothesized that the circadian system regulates
innate immune responses in order to maximize antimicrobial
responses at the time of the day when they are needed most.
In order to evaluate whether this would be a common finding
among multiple innate immune recognition mechanisms or, to
the contrary, would be exclusive for a particular innate immune
pathway, we isolated peritoneal macrophages from circadian-
deficient Per2 mutant mice and challenged them with different
PAMPs targeting multiple TLRs. Per2Brdm1 mice carry a mutant
Per2 gene with a deletion in the Per-Arnt-Sim (PAS) dimerization
domain, which is critical for the interaction with other clock
proteins, thus rendering a nonfunctional PER2 protein and
a defective circadian molecular clock (Zheng et al., 1999).
Upon challengewith CpGODNs (TLR9 ligand), Per2Brdm1macro-
phages produced significantly less TNF-a and IL-12 than wild-
type (WT) macrophages (Figure 1A). This finding was restricted
to TLR9-mediated responses, given that cytokine production
in Per2Brdm1 macrophages was comparable to that seen in WT
macrophages when PAMPs other than CpG ODNs were used
(Figure 1A).
Circadian Regulation of Tlr9 Expression
We then considered that the circadian clock could be modu-
lating TLR9-dependent cytokine production by controlling Tlr9
expression. The circadian molecular clock can be triggered
in vitro by exposing immortalized or primary cells to a high serum
concentration (serum shock) (Balsalobre et al., 1998). Triggering
of the circadian clock is evidenced by the observation of circa-
dian (near 24 hr period) oscillations in the expression of canonical
clock genes (Balsalobre et al., 1998).We exploited this system to
entrain the circadian clock in murine peritoneal macrophages
in vitro and assessed the subsequent temporal variations in
gene expression. We detected robust circadian oscillations in
the mRNA expression of the canonical clock genes Per2 and
Nr1d1 (Figure 1B) after serum shock, indicating that macro-
phages are equipped with a functional circadian molecular
clock. This finding is consistent with other reports using resident
peritoneal macrophages and other innate immune cells (Arjona
and Sarkar, 2005; Keller et al., 2009). In line with our hypothesis,
we found that along with these two clock genes, Tlr9 mRNA
expression also fluctuated in a circadian fashion after serum252 Immunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc.shock treatment; two significant expression peaks 24 hr apart
were detected (Figure 1C). This pattern was not seen when the
mRNA expression of Tlr4 or Tlr7were analyzed. Canonical clock
gene expression has previously been analyzed in the spleen of
Per2Brdm1 mice over the daily cycle. In these mice, Per1 and
Per2 expression rhythms are phase advanced, overall transcript
levels of Per1, Per2, and Bmal1 are increased, and Bmal1
expression does not undergo significant daily oscillations (Arjona
and Sarkar, 2006). When comparing Tlr9 expression between
WT and Per2Brdm1 peritoneal macrophages 20 hr after serum
shock (peak of Tlr9 expression), Tlr9 mRNA expression in
Per2Brdm1 macrophages was significantly lower than those in
WTmacrophages (Figure 1D). Regardless of whether this finding
reflects an overall reduction of Tlr9 expression or to a change
in its rhythmic parameters, it shows that disruption of the
molecular clock affects the Tlr9 mRNA expression profile after
serum shock-induced circadian entrainment.
Circadian Transcription Factors Bind the Tlr9 Promoter
The core molecular clock machinery generates circadian
outputs by coordinating the expression of the clock-controlled
genes (CCGs). Direct regulation of target genes is accomplished
by the core circadian transcription factors CLOCK:BMAL1
binding to E-boxes in the promoter region and activating tran-
scription (Ueda et al., 2005). We examined the murine Tlr9 prox-
imal promoter region as described by Schroder et al. (2007) and
found two putative noncanonical E-boxes (Leclerc and Boock-
for, 2005) near the transcription initiation site (Figure S1 available
online). We examined the binding of CLOCK:BMAL1 hetero-
dimer to the Tlr9 promoter by conducting ChIP assays in
serum-entrained peritoneal macrophages (Figure 1E), given
that the Tlr9 promoter was amplified by PCR when pulling
down with BMAL1 or CLOCK antibodies. In addition, we found
that under serum shock conditions, peak Tlr9mRNA expression
in Clock siRNA-transfected macrophages were significantly
lower than those found in control siRNA-transfected or mock-
transfected macrophages (Clock siRNAs did not have an effect
on Tlr9 expression 6 hr after serum shock) (Figure 1F), which
further supports the notion that CLOCK:BMAL1 regulates Tlr9
expression.
In Vivo Daily and Circadian Variations in Tlr9 Expression
and Function
We then evaluated the existence of in vivo daily variations in Tlr9
expression in immune tissue and cells obtained every 4 hr from
mice entrained to a 12 hr light and 12 hr dark cycle (LD). Splenic
Tlr9 mRNA expression showed a daily rhythm that peaked at
Zeitgeber time (ZT) 19, coinciding with the mouse active phase
(lights off at ZT12; Figure 2A). Of note, the splenic mRNA expres-
sion of Tlr4 and Tlr7 did not show substantial daily fluctuations,
which is in line with the circadian specificity for TLR9 shown in
the in vitro experiments. Tlr9 is highly expressed in antigen-pre-
senting cells such as macrophages, B cells, and DCs (Hornung
et al., 2002). Figure 2B shows that in macrophages, Tlr9 mRNA
expression showed a daily rhythm that peaked at ZT11, whereas
in B cells, Tlr9 mRNA reached maximum amounts from ZT15
through ZT19 (Figure 2C). In contrast, no substantial changes
in the expression of Tlr9 mRNA over the daily cycle were seen
in DCs (Figure 2D), which indicates that the circadian control of
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Figure 1. Circadian Control of TLR9 Expression and Function
(A) WT and Per2Brdm1 thioglycolate-elicited peritoneal macrophages were challenged with PAMPs targeting different TLRs. TNF-a and IL-12 amounts in culture
supernatants were determined by ELISA 16 hr after challenge from 4 independent experiments; *, significantly different from WT.
(B) Circadian oscillations of Nr1d1 and Per2 mRNA expression in serum-entrained peritoneal macrophages. An asterisk marks significant difference from time
points showing the lowest mRNA expression.
(C) Circadian oscillations of Tlr mRNA expression in serum-entrained peritoneal macrophages, significantly different from T10 and T30 time points.
(D) Impaired serum-induced Tlr9 expression in Per2Brdm1 peritoneal macrophages, significantly different from T6.
(E) ChiP analysis of CLOCK and BMAL1 binding to the Tlr9 promoter. Tlr9 (top) and Gapdh (bottom) promoter specific sequences were amplified by qPCR from
DNA-protein complexes pulled down with specific antibodies.
(F) Impaired Tlr9 expression after siRNA-mediated knockdown of Clock, significantly different from T6.
(A–D and F) Error bars represent means ± SEM. *p < 0.05; significantly different as per two-sided t test. See also Figure S1.
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Circadian Control of Toll-like Receptor 9TLR9-mediated responses may be restricted to specific immune
cell types. A defining feature of circadian rhythms is that the
rhythm persists in the absence of an environmental cue (e.g.,
light-dark cycle), therefore, we assessed the Tlr9 in vivo expres-
sion rhythm in the spleen, macrophages, B cells, and DCs under
constant darkness (DD). Despite detecting some changes in
phase, amplitude, or acrophase, the Tlr9 rhythm is maintained
in the spleen, macrophages, and B cells (Figures 2E–2G) of
mice kept in DD. We verified the clock was functional in the
spleen of these animals by assessing canonical clock gene
expression (Figure S2A). We did not observe marked daily fluc-
tuations in Tlr9 mRNA expression in DCs from LD mice (Fig-
ure 2D); however, under DD conditions, a significant expressionpeak was detected from circadian time (CT) 15 to CT23 (Fig-
ure 2H). The absence of marked Tlr9 mRNA fluctuations in DCs
under LD conditions is likely due to light masking. The persis-
tence of 24 hr rhythms in Tlr9 mRNA expression in splenic
macrophages and B cells obtained from mice kept in DD further
demonstrates the circadian nature of these rhythms.
Daily variations in TLR9were also detected at the protein level.
TLR9 protein amounts measured by immunoblot were signifi-
cantly higher at ZT19 in whole-spleen lysates, splenic CD11b+
and CD19+ cells isolated by magnetic separation (Figures 2I–
2K and S2B) when compared to ZT7. We also observed a signif-
icant increase in TLR9 amounts by flow cytometry in MHC-II+
and CD19+ cells isolated from the spleen at ZT19 whenImmunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc. 253
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Figure 2. In Vivo Daily and Circadian Oscillations of Tlr9 mRNA and Protein Amounts
Daily oscillations of Tlr mRNA levels in (A) spleen, (B) macrophages, (C) B cells, (D) DCs. Relative mRNA amounts at each time point were calculated as the
percentage of the maximum value over the 24 hr period. Data are mean ± SEM. n = 5 mice per time point (A), and n = 10 animals per time point (B), compiled
from two independent experiments; n = 15 animals per time point (C), compiled from three independent experiments; n = 15 animals per time point (D), compiled
from three independent experiments. Oscillations of Tlr9 mRNA amounts under DD in (E) spleen, (F) macrophages, (G) B cells, and (H) DCs are shown. Data
are mean ± SEM. n = 5 mice per time point (E–H). *p < 0.05, **p < 0.01 (A–H), significantly different from the lowest amount of mRNA (nadir) by one-way ANOVA
with the Dunnett posttest. Increased TLR9 protein amounts at ZT19 in (I) spleen, (J) splenic CD11b+ cells, and (K) splenic CD19+ cells are shown. TLR9
protein amounts were determined by immunoblotting and actin amounts were used as a normalizing factor. Relative protein amounts were calculated as the
percentage of the maximum value. n = 3 animals per time point (I), and n = 10 animals per time point (J), compiled from two independent experiments.
n = 15 animals per time point (K), compiled from three independent experiments. As shown in (L), TLR9 amounts were determined by flow cytometry in MHC-II+
cells (top) and CD19+ cells (bottom). n = 5 animals per time point. Data are mean ± SEM (I–L). *p < 0.05, significantly different from ZT7 as per two-sided t test.
See also Figure S2.
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Circadian Control of Toll-like Receptor 9compared to those isolated at ZT7 (Figure 2L). Variations in TLR9
protein amounts mimicked those of Tlr9 mRNA expression.
Nevertheless, TLR9 protein degradation, not only mRNA
synthesis, may also determine the daily variations in TLR9 overall
protein amounts, as it has been shown for circadian SUMOyla-
tion of BMAL1 (Cardone et al., 2005).
When mice were challenged with CpG ODNs at ZT19
(increased Tlr9 expression; Figures 2A and 2I), they presented254 Immunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc.with higher splenic mRNA expression of TNF-a, MCP-1, CD80,
and CD86 at 2 hr after challenge versus mice that were chal-
lenged at ZT7 (Figure 3A). To verify that the differences seen in
challenged animals were not simply due to an oscillation in
baseline amounts, we determined that there was no significant
difference in mRNA amounts of these cytokines and costimula-
tory molecules in unchallenged mice over the daily LD cycle
(Figure S3). To evaluate whether these temporal differences in
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Figure 3. Functional Repercussions of the In Vivo Tlr9 Daily Rhythm
(A) Increased TLR9-mediated cytokine response at ZT19. Cytokine and costimulatory molecule mRNA amounts were determined 2 hr after CpG challenge, n = 10
mice per time point, compiled from two independent experiments.
(B) TLR9-mediated cytokine and costimulatory response in WT and Per2Brdm1 mice. Cytokine and costimulatory molecule mRNA amounts in the spleen were
determined 2 hr after CpG. CD86 mRNA amount plotted as the percentage of the maximum value, n = 10 animals per time point, compiled from two independent
experiments.
(C) Increased splenic Tlr9mRNA expression in Per2Brdm1mice at ZT19. Relative mRNA amounts were calculated as the percentage of the maximum value, n = 8
animals per group compiled from two independent experiments.
(D) Decreased Tlr9 mRNA expression in splenic macrophages isolated from Per2Brdm1 mice at ZT19, n = 5.
(C and D) TLR9 protein amounts were determined by immunoblotting. Actin amounts were used as a normalizing factor.
(E) Increased TLR9 protein amounts in splenic CD19+ cells in Per2Brdm1 at ZT19; n = 5.
(A–E) Data are mean ± SEM. *p < 0.05, significantly different as per two-sided t test. See also Figure S3.
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Circadian Control of Toll-like Receptor 9TLR9-mediated innate responses were under circadian control,
we also compared the in vivo CpG-induced cytokine response
of WT mice to that of Per2Brdm1mice. We found that, when chal-
lenged at ZT19, circadian-deficient mice exhibited a reducedCpG-induced cytokine response (TNF-a, MCP-1) but had signif-
icantly higher splenic mRNA expression of CD86 (Figure 3B)
compared to WT mice. These seemingly discordant results
may be due to immune cell specific differences in the circadianImmunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc. 255
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Circadian Control of Toll-like Receptor 9regulation of TLR9, as related to both overall expression and
rhythmic parameters (e.g., rhythm phase). We also found that
Tlr9 mRNA expression was higher in the spleen but lower in
splenic macrophages of unchallenged Per2Brdm1 mice versus
WT mice at ZT19 (Figures 3C and 3D). When examining protein
amounts between unchallenged WT and Per2Brdm1 mice at
ZT19, we found that TLR9 amounts are higher in Per2Brdm1
splenic B cells (Figure 3E). Collectively, these data demonstrate
that there are in vivo daily and circadian variations in Tlr9 expres-
sion that correlate with TLR9 responsiveness. Importantly,
normal TLR9 expression and function is affected by a loss-of-
function mutation in Per2, a key component of the circadian
molecular clock.
Circadian Control of TLR9 Ligand-Adjuvanted Vaccine
Responsiveness
Innate immune activation is critical for mounting an effective
adaptive immune response (Medzhitov and Janeway, 1999),
and CpGODNs are being evaluated in the clinic for their adjuvant
potential (Huang et al., 2008; Kline, 2007; Vollmer and Krieg,
2009). We examined whether vaccine responsiveness could be
enhanced by conducting a CpG ODN-adjuvanted immunization
at the time of increased TLR9 expression and function. Mice
were injected intraperitoneally with a mixture of OVA and CpG-
ODNs at either ZT7 or ZT19 and received a boost 14 days later
at their corresponding time point. Four weeks after the first
immunization, lymph nodes were harvested and total lymph
node cells were cultured for measuring OVA-induced prolifera-
tion and IFN-g production. We found that lymphocyte cultures
obtained from mice that were immunized 4 weeks earlier with
OVA-CpG ODNs at ZT19 (increased TLR9 responsiveness)
showed a substantially increased Ag-induced proliferation and
IFN-g production compared to mice that were immunized at
ZT7 (Figures 4A and 4B). This phenomenon was reproduced in
multiple independent experiments. Of note, this difference was
not seen when control ODNs or Pam3Cys (a PAMP that is not
detected by TLR9) were used as adjuvants (Figures 4C and
4D). We also immunized WT and Per2Brdm1 mice with OVA-
CpG ODNs at ZT19 to determine whether their adaptive immune
responses differed. Lymphocyte cultures obtained from OVA-
CpG immunized Per2Brdm1 mice showed an increased Ag-
induced proliferation when compared to WT mice (Figure 4E),
which correlated with increased TLR9 protein amounts in
Per2Brdm1 mice B cells (Figure 3E). These results show that the
daily variations in TLR9 responsiveness have long-term reper-
cussions in the magnitude of the adaptive immune response,
which is also modulated by Per2, a canonical component of
the circadian molecular clock.
Diurnal Variations in Disease Severity in
a TLR9-Dependent Mouse Model of Sepsis
Next, we investigated whether the circadian regulation of TLR9
expression could mediate inflammatory disease in vivo. During
sepsis, an infection leads to a systemic inflammatory response
syndrome (SIRS), which is harmful to the host. Septic patients
have a heightened risk of mortality between the hours of 2 and
6 a.m. (Hrushesky and Wood, 1997). However, the reasons for
this are unknown. We examined whether daily rhythms affect
disease pathogenesis in the mouse cecal ligation and puncture256 Immunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc.(CLP) model, wherein the mouse cecum is punctured allowing
commensal bacteria to escape into the peritoneum, leading to
SIRS and polymicrobial sepsis. This model was previously
shown to be TLR9-dependent (Plitas et al., 2008; Yasuda
et al., 2008); hence, we reasoned that the daily variations in
Tlr9 expression and function might affect sepsis pathogenesis
after CLP.
We performed CLP surgeries and sham controls at the nadir
and peak of splenic Tlr9 expression (ZT7 and ZT19, respec-
tively). Mice that underwent sham surgeries at either ZT7 or
ZT19 survived and exhibited no signs of sepsis (Figures 5A–
5H). In line with our hypothesis, mice that underwent CLP at
ZT19 exhibited a worse sepsis phenotype versus mice that
underwent CLP at ZT7, including: earlier mortality (Figure 5A,
ZT19 CLP MST = 31 hr, n = 28; ZT7 CLP MST = 45 hr, n = 27),
worse disease score (Figure 5B), more severe hypothermia (Fig-
ure 5C), higher concentrations of serum creatine kinase (Fig-
ure 5D, indicative of heart or skeletal muscle damage), higher
concentrations of inflammatory mediators in the serum,
including cytokines IL-6 and IL-12p40 and chemokine MCP-1
(Figures 5E–5G), and greater numbers of bacterial CFU in the
peritoneum (Figure 5H).
DISCUSSION
Our findings unveil a direct molecular link between the circadian
system and the innate immune system. A nonfunctional Per2
gene affects TLR9 expression, TLR9 responsiveness, and abso-
lute levels of the adaptive response when a TLR9 ligand is em-
ployed as an adjuvant. We showed that the circadian clock
controlled the expression of the pattern recognition receptor
TLR9, and this regulation translated to daily variations in TLR9
responsiveness as measured by cytokine response and expres-
sion of costimulatory molecules. TLR9 is highly expressed in
various types of antigen-presenting cells (Hornung et al., 2002),
and our data indicate that the circadian regulation and TLR9
rhythm phase is unique to each immune cell type and different
from the overall rhythm found in the spleen. Of note, DCs did
not exhibit significant changes in Tlr9 mRNA expression
throughout the daily cycle. After challenge with CpG ODNs,
WT mice had an increased cytokine response but lower CD86
mRNA expression than Per2Brdm1 mice, and Per2 mutation
affected Tlr9 mRNA and protein expression differently depend-
ing on the tissue or cell type analyzed, reflecting the intricate
web woven between the circadian clock and TLR9 expression
and function in each of these specific immune cells. Further
contributing to this in vivo complexity is the fact that some
immune cells may not possess a functional circadian clock, yet
it remains possible that PER2 could have a clock-independent
influence on the TLR9 pathway. It is likely that Per2 and other
canonical components of the molecular clock may modulate
the expression and function of TLR9 in different ways depending
on the immune cell type.
The circadian system may target other innate immune path-
ways depending on the immune cell type or on the activation
status. For example, transcriptional analyses in resident perito-
neal macrophages have revealed circadian fluctuations in
several aspects of the TLR4-LPS response pathway (Keller
et al., 2009). Although the latter does not provide direct evidence
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Figure 4. Enhanced Adaptive Immunity in Mice Vaccinated at ZT19 when Using a TLR9 Ligand as Adjuvant
(A and E) Enhanced lymphocyte proliferation in total lymph node cell cultures obtained frommice immunized with CpG-OVA at ZT19 compared to ZT7 or WT and
Per2Brdm1mice at ZT19. Error bars represent the average of four replicates from lymphocyte cultures pooled from five mice per treatment and time point. Results
were reproduced in multiple independent experiments.
(B–D) Enhanced OVA-induced IFN-g production in lymphocyte cultures obtained from mice challenged with CpG-OVA at ZT19 compared to ZT7. Mice were
immunized with OVA-CpG (B) OVA-control ODNs or OVA-CpGODNs (C) andOVA-Pam3cys or OVA-CpG (D) at the indicated time points. Error bars represent the
average of four replicates from lymphocyte cultures pooled from five mice per treatment and time point. Results were reproduced in three independent
experiments.
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pathway being directly controlled by canonical molecular clock
components, it clearly shows that circadian mechanisms act
at multiple levels in innate response pathways, including cyto-
kine expression. Although Keller et al. assessed immune
response rhythms after challenge with a PAMP (LPS), in this
manuscript we have focused on the basal rhythms in the
expression and function of the sensing molecule TLR9 and
provided direct evidence for its circadian control. Thus, circa-
dian mechanisms seem to regulate immune response pathways
at multiple levels and both in basal and postchallenge condi-
tions. Perhaps an important role for this circadian control is to
ensure the temporal coincidence of all the necessary molecular
components of the response, from those needed to sense the
pathogen to those required for providing the effector molecules.
In 1960, Halberg and colleagues reported that the mortalityupon LPS-induced endotoxic shock in mice depends highly
on the time of day when the mice are challenged, which further
suggests that other immune response pathways triggered by
pathogen recognition may be also subject to circadian control
(Halberg et al., 1960).
Exposure to microbial pathogens may be higher at certain
times of the day because of the intrinsic 24 hr rhythms of
the host (activity, feeding, and behavior). Moreover, many
pathogens that cause disease throughout the world, such as
flaviviruses and Plasmodium falciparum, are transmitted by
mosquitoes, which show a marked daily rhythm in their biting
activity (Githeko et al., 1996). It is therefore plausible that TLR9
and possibly other components of the innate immune system
have evolved a circadian regulation in order to maximize its
efficiency at the time of the day when the encounter with the
pathogen is more likely to occur. In contrast, arthropod-borneImmunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc. 257
Figure 5. Daily Variations in TLR9 Responsiveness influence disease severity in the TLR9-Dependent CLP Mouse Model of Sepsis
A more severe sepsis pathophysiology ensued in mice that underwent CLP at ZT19 versus ZT7 including: (A) earlier mortality; (B) worse disease score (disease
was scored as follows: 0 = bright, alert, responsive; 1 = slightly lethargic; 2 = lethargic and hunched; 3 = very lethargic, hunched and shaky; 4 = dead); (C) more
severe hypothermia; (D) higher concentration of serum creatine kinase; higher concentration of serum inflammatory mediators including (E) IL-6, (F) Il-12/23p40,
and (G) MCP-1; and (H) higher amounts of bacterial CFU in the peritoneum.
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in order to infect the host when innate response mechanisms
are at the lowest efficiency.258 Immunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc.In support of the translational potential of our findings into
the clinic, we have identified up to three noncanonical E-boxes
in the human Tlr9 promoter at positions 513 (CAGGTG),
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Circadian Control of Toll-like Receptor 9386 (CAGCTG), and 148 (CATTTG). Studies assessing the
possible circadian control of Tlr9 expression in humans are war-
ranted. The results described herein also demonstrate that the
daily variations in TLR9 responsiveness modulate the efficacy
of CpG ODN-adjuvanted immunization. Several TLR9 agonists
are undergoing extensive clinical evaluation as adjuvants and
immunomodulators that could be useful for treatment of impor-
tant conditions such as multiple sclerosis, asthma, and cancer
(Vollmer and Krieg, 2009). Considering not only the dosing and
immunization timing but also the degree of proper circadian
entrainment in patients may be critical for assessing and maxi-
mizing the prophylactic and therapeutic efficacy of these agents.
Our findings with the TLR9-dependent CLP model indicate
that the daily variations in TLR9 expression and function are
correlated with the progression and severity of sepsis. Given
the observation that septic patients are at increased risk of
mortality between the hours of 2 and 6 a.m. (Hrushesky and
Wood, 1997), future studies are warranted to determine whether
human patients also exhibit circadian regulation of TLR9 and
other aspects of the innate immune response (several PRRs
other than TLR9 would be concurrently activated during sepsis).
If this proves to be the case, septic patients might benefit from
receiving immunomodulatory therapies during the hours when
they are most vulnerable. Furthermore, patients in the ICU often
have disturbed sleep patterns, due to noise, nocturnal light
exposure, and medications; it will be important to investigate
how these factors influence TLR9 expression and innate immune
responses.
EXPERIMENTAL PROCEDURES
Animals
Two- to three-month-old C57BL/6J and Per2 mutant (mPer2Brdm1) male mice
(Jackson ImmunoResearch Laboratories) were fed rodent chow ad libitum,
maintained under constant environmental conditions, and entrained to a
12 hr light/12 hr dark cycle (light period from 7:00 a.m. to 7:00 p.m.) for at
least 2 weeks before experiments. The Per2Brdm1 mutant strain was originally
developed by A. Bradley and has a genetic background of C57BL/6 (Zheng
et al., 1999). For most daily-cycle experiments, animals were euthanized at
10:00 a.m., 2:00 p.m., 6:00 p.m., 10:00 p.m., 2:00 a.m., and 6:00 a.m. These
time points correspond with Zeitgeber times (ZT) 3, 7, 11, 15, 19, and 23,
respectively. For experiments under constant conditions, dark/dark (DD),
animals were held in constant darkness for 3 days prior to sampling at circa-
dian times (CT) 3, 7, 11, 15, 19, and 23. Tissues were immediately collected
for further processing as described below. During the study, animal care
and treatment complied with National Institutes of Health policy, were in accor-
dance with institutional guidelines, and were approved by the Yale Institutional
Animal Care and Use Committee.
Cells
Peritoneal macrophages from C57BL/6J (Jackson ImmunoResearch Labora-
tories) or Per2Brdm1 of the same genetic background were obtained 3–4 days
after i.p. injection with 3% thioglycollate broth (REMEL) by peritoneal lavage.
Macrophages were purified by adherence in accordance with standard proce-
dures and cultured overnight in RPMI 1640 containing 10%FBSplus penicillin-
streptomycin (Invitrogen Life Technologies).
In Vitro Entrainment
Cells were cultured in Dulbecco’s modified eagle medium (DMEM) supple-
mented with 10% FBS and transferred to a six-well cell culture plate
(BD Biosciences) where they were incubated overnight. On the following
day, the medium was aspirated, and cells were washed with 1 ml of warm
PBS and incubated for 2 hr in 2 ml of serum-free medium. At the conclusionof 2 hr, the cells were serum shocked with 1 ml of FBS (50% final concentra-
tion). The medium containing 50% serum was replaced with serum-free
medium after 2 hr. Cells were harvested every 4 hr, lysed in the appropriate
buffer, and stored at 80C until their later use for RNA extraction or immuno-
blot analysis.
PAMP Challenge and Cytokine Measurements
Thioglycollate-elicited peritoneal macrophages from WT and Per2Brdm1 mice
were plated and challenged the following day with Pam3Cys (500 ng/ml), lip-
oteichoic acid (LTA, 10 mg/ml), poly(I:C) (100 mg/ml), LPS (100 ng/ml), flagellin
(5 mg/ml), imiquimod (10 mg/ml), or unmethylated CpG-DNA (10 mg/ml)—
synthetic oligonucleotides containing unmethylated CpG dinucleotides in
particular sequence contexts. We employed CpG ODNs from InvivoGen
(ODN 1826), which are type B specific for mouse TLR9. The 20-mer sequence
is 50-tccatgacgttcctgacgtt-30. TNF-a and IL-12 amounts in culture superna-
tants were determined by ELISA 16 hr after challenge with commercially
available ELISA kits (R&D Systems).
Cell Isolation and Purification
Spleens were collected in RPMI 1640 (Invitrogen Life Technologies) supple-
mented with 10%FBS and placed on ice. For obtaining homogeneous spleno-
cyte suspensions, each spleen was homogenized in 1 ml of RPMI, filtered
through a 70 mM nylon cell strainer (BD Biosciences), and spun down for
5min at 1,200 rpm. The supernatant was removed and cells were resuspended
in 3 ml red cell lysing buffer (Sigma) and incubated for 10 min at room temper-
ature. Sevenmilliliters of PBSwere added to the cell suspension and cells were
spun down for 5 min at 1,200 rpm. The supernatant was removed and cells
were resuspended in 3 ml PBS and aliquoted into separate tubes for labeling
with microbeads and subsequent cell separation. CD11b, CD11c, and CD19
mouse microbeads (Miltenyi Biotec) were used for labeling splenic macro-
phages, dendritic cells, and B cells, respectively. The labeling was followed
according to themanufacturer’s instructions and the autoMACSPro Separator
(Miltenyi Biotec) was utilized for the magnetic cell separation. The purity of the
enriched fractions was assessed by flow cytometry with FITC-conjugated
CD11b, CD11c, and CD19 antibodies (Miltenyi Biotech). The enrichment
method consistently yielded a purity of 90%, 60%, and 80% for CD11b-,
CD11c-, and CD19-positive cells, respectively. Immediately after separation,
enriched cells were lysed in appropriate buffers for later RNA extraction and
protein analysis. For flow cytometry, cells were fixed and permeabilized before
staining with purified fluorescent monoclonal anti-TLR9 antibody from Imge-
nex (clone 26C593.2).
RNA Extraction and Quantitative PCR
Total RNA was isolated with the RNeasy mini kit (QIAGEN). cDNA was synthe-
sized with the high capacity cDNA reverse transcription kit (Applied Bio-
systems). Relative quantitation of mRNA was performed by quantitative
PCR via TaqMan Gene Expression Assays (Applied Biosystems) with a real-
time PCR 7500 Fast System (Applied Biosystems). Analyses were performed
with the standard curve method with b-actin as the normalizing endogenous
control. RNA from enriched cells was isolated with the RNeasy Plus-Micro
kit (QIAGEN). As a result of low expression and a limited amount of cDNA,
the TaqMan PreAmp Master Mix Kit (Applied Biosystems) was used in
conjunction with TaqMan Gene Expression Assays (Applied Biosystems) for
examining mRNA amounts of selected genes from individual cell types. The
procedure was followed in accordance with the manufacturer’s instructions.
Protein Isolation and Immunoblot Analysis
For protein analysis, spleen tissue and cells were lysed in T-PER and M-PER
protein extraction reagent (Thermo Scientific), respectively. Protein samples
were subjected to standard SDS-PAGE electrophoresis, transferred to a nitro-
cellulose membrane, and probed with TLR9 and beta Actin polyclonal Ab
(Imgenex). After chemiluminescence detection with ECL immunoblot detec-
tion kit (Amersham), densitometry analyses were performed with ImageJ64
software.
ChIP, EMSA, and si-RNA-Mediated Knockdown of Clock
ChIP was performed with EZ ChIP Chromatin Immunoprecipitation Kit
(Millipore) and EMSA was performed with the LightShift ChemiluminescentImmunity 36, 251–261, February 24, 2012 ª2012 Elsevier Inc. 259
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with the manufacturer’s instructions. Clock expression was knocked down
with Clock siRNA (Santa Cruz Biotechnology) and the transfection protocol
was followed in accordance with the manufacturer’s instructions (Santa
Cruz Biotechnology). Clock antibody (Santa Cruz Biotechnology) was used
for verifying knockdown in CLOCK protein amount.
Immunization Experiments
Mice entrained to a 12 hr light/12 hr dark cycle were injected intraperitoneally
with 10 mg OVA and 30 mg CpG ODNs (InvivoGen) at either ZT7 or ZT19. Two
weeks later, mice received a boost (10 mg OVA and 30 mg CpG ODNs) at their
corresponding time. Twenty-eight days after the initial OVA CpG ODN chal-
lenge, mice were sacrificed and lymph nodes were pooled, according to
time of immunization or mouse strain, in cell culture medium (RPMI supple-
mented with 10% FBS). Lymph nodes were homogenized and passed through
a 70 mM nylon cell strainer (BD Biosciences). Lymphocytes were spun down,
resuspended in 10 ml of medium, and counted with a hemocytometer. We
seeded 96-well U-bottom tissue culture plates (BD Biosciences) with 105 or
106 cells per well for lymphocyte proliferation or IFN-g production, respec-
tively, in 200 ml of medium. Cells were allowed to incubate for 1 hr in a 37C
CO2 incubator and then cells were either challenged with 20 mg of OVA and
1 mg of Concanavalin A (Sigma) or left unstimulated. Lymphocyte proliferation
was determined with the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega). IFN-gwas determined with theMouse IFN-gHigh Sensitivity
ELISA (eBioscience).
CLP and Related Measurements
CLP was performed as previously described (Rittirsch et al., 2009) (75% of the
cecum was ligated and pierced with a 21G needle). Mice received 1 ml
warmed saline s.c. postoperatively and buprenorphine analgesia at 12 hr inter-
vals. Surface temperature was determined with an infrared thermometer.
Blood was collected by retro-orbital bleed and serum was prepared in micro-
tainer tubes (Becton Dickinson, San Jose, CA). ELISA kits for IL-6, IL-12/
23p40, and MCP-1 (eBiosciences, San Diego, CA) and the CK reagent set
(Pointe Scientific, Canton, MI) were used per the manufacturer’s instructions.
Peritoneal lavage was plated on BBL agar plates so that bacterial CFU could
be determined.
Statistical Analysis
Data were analyzed with GraphPad Prism 4.0b (GraphPad, San Diego, CA).
For parametric comparisons, we employed a two-way t test for pairwise
comparisons and the analysis of variance test for repeated-measures. For
nonparametric comparisons, we employed Mann-Whitney for pairwise
comparisons and Kruskal-Wallis for comparison of three or more groups.
Survival curves were compared by the Logrank test. *p < 0.05 was considered
to be statistically significant, and **p < 0.01 was considered to be highly signif-
icant. Unless otherwise stated, p values result from the statistical comparison
of mean values obtained from independent experiments.
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